Karyopharm Therapeutics Company Profile (NASDAQ:KPTI)

Karyopharm Therapeutics trades on the NASDAQ under the ticker symbol "KPTI."

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) released its quarterly earnings results on Tuesday, August, 8th. The company reported ($0.64) earnings per share (EPS) for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.64). Karyopharm Therapeutics had a negative net margin of 67,267.47% and a negative return on equity of 70.42%. The firm's quarterly revenue was down 95.0% compared to the same quarter last year. During the same period last year, the company earned ($0.84) EPS. View Karyopharm Therapeutics' Earnings History.

Karyopharm Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, November, 6th 2017. View Earnings Estimates for Karyopharm Therapeutics.

8 equities research analysts have issued 12 month price objectives for Karyopharm Therapeutics' shares. Their predictions range from $14.00 to $19.00. On average, they anticipate Karyopharm Therapeutics' share price to reach $16.25 in the next year. View Analyst Ratings for Karyopharm Therapeutics.

Here are some recent quotes from research analysts about Karyopharm Therapeutics stock:

• 1. According to Zacks Investment Research, "Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs for the treatment of cancer and other major diseases. It serves the healthcare industry throughout the United States. Karyopharm Therapeutics, Inc. is based in United States. " (7/18/2017)
• 2. Cantor Fitzgerald analysts commented, "Support for KPTI’s DLBCL program (SADAL) could build with a presentation at the EHA (Abstract S469) in June." (5/15/2017)
• 3. HC Wainwright analysts commented, "Although selinexor is still technically on a partial clinical hold in the U.S., due to an omitted table in its most recent investigator's brochure, Karyopharm focused its 4Q call on the steady progress being made in its development across a range of indications. Having received its requested information, we believe the FDA should release the partial clinical hold well in advance of 4/9, and believe this hiccup will have no material impact on enrollment of the selinexor trials. On its call, Karyopharm noted that it had completed enrollment of its Phase 2/3 SEAL trial of selinexor in liposarcoma patients and expects to report topline data in mid-2017. While we do not currently include liposarcoma in our estimates, we note that selinexor had shown promising and durable stable disease outcomes in a Phase 1 study in sarcomas with a better PFS observed than the last prior regimen (19.4 v. 7.7 weeks) with 43% of liposarcoma patients achieving stable disease having a 4+ month response. Separately, Karyopharm provided updates on selinexor in multiple myeloma noting that the expanded STORM trial in penta-refractory myeloma patients was on track to read out in early-2018, the Phase 3 BOSTON trial was expected to start by April, and the Phase 1b/2 STOMP trial was to begin enrollment of a 44- patient Darzalex (daratumumab) combination arm, expected to read out in late-2017/early-2018. As of December, Karyopharm had a cash position of $175.5M, which the company believes sufficient to fund operations through 2018. In 2017, Karyopharm expects its cash burn to be $85-90M. We are maintaining our KPTI price target of $14, based on a sum-of-the-parts DCF consisting of $6 for selinexor in MM, $4 sel in DLBCL, and $4 cash." (3/17/2017)

Some companies that are related to Karyopharm Therapeutics include Omeros Corporation (OMER), Epizyme (EPZM), Five Prime Therapeutics (FPRX), Athenex (ATNX), Amarin Corporation PLC (AMRN), Retrophin (RTRX), ZIOPHARM Oncology (ZIOP), REGENXBIO (RGNX), Intra-Cellular Therapies (ITCI), Vanda Pharmaceuticals (VNDA), Reata Pharmaceuticals (RETA), Akebia Therapeutics (AKBA), Keryx Biopharmaceuticals (KERX), Flexion Therapeutics (FLXN), La Jolla Pharmaceutical Company (LJPC), Aduro Biotech (ADRO), Cytokinetics, Incorporated (CYTK) and PTC Therapeutics (PTCT).

Karyopharm Therapeutics' management team includes the folowing people:

• Sharon Shacham Ph.D., President, Co-Founder, Chief Scientific Officer, Director
• Michael G. Kauffman M.D. Ph.D., Co-Founder, Chief Executive Officer and Director
• Michael J. Todisco CPA, Interim Chief Financial Officer, Vice President - Finance, Assistant Treasurer
• Christopher B. Primiano, Vice President- Corporate Development, General Counsel, Secretary
• Dilara McCauley Ph.D., Vice President - Product Leadership
• Brian Austad Ph.D., Senior Director, Head - Pharmaceutical Sciences
• Ran Frenkel, Chief Development Operations Officer
• Barry E. Greene, Lead Independent Director
• Mikael Dolsten M.D., Ph.D., Director
• Mansoor Raza Mirza M.D., Director and Clinical Advisor

Karyopharm Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include FMR LLC (9.18%), Palo Alto Investors LLC (7.36%), Franklin Resources Inc. (6.58%), Vanguard Group Inc. (3.44%), Tekla Capital Management LLC (1.61%) and State Street Corp (1.09%). Company insiders that own Karyopharm Therapeutics stock include Christopher Brett Primiano, Ltd Chione, Mansoor Raza Mirza and Ran Frenkel. View Institutional Ownership Trends for Karyopharm Therapeutics.

Karyopharm Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Franklin Resources Inc., Citadel Advisors LLC, Nationwide Fund Advisors, Goldman Sachs Group Inc., Wells Fargo & Company MN, Bank of New York Mellon Corp and Parametric Portfolio Associates LLC. Company insiders that have sold Karyopharm Therapeutics stock in the last year include Christopher Brett Primiano, Mansoor Raza Mirza and Ran Frenkel. View Insider Buying and Selling for Karyopharm Therapeutics.

Karyopharm Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Candriam Luxembourg S.C.A., Tekla Capital Management LLC, Northern Trust Corp, Palo Alto Investors LLC, Dimensional Fund Advisors LP, State Street Corp and TIAA CREF Investment Management LLC. View Insider Buying and Selling for Karyopharm Therapeutics.

Shares of Karyopharm Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Karyopharm Therapeutics stock can currently be purchased for approximately $10.63.